Local mast cell histamine and plasma histamine levels in neurofibromatosis type 1

Acta Dermato-Venereologica

Volumn 90, Issue 6, 2010, Pages 637-639

  Yoshida, Yuichi ^a   Adachi, Koji ^a   Yamamoto, Osamu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE;

ADOLESCENT; ADULT; AGED; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE PLEXIFORM NEUROFIBROMA; FEMALE; HISTAMINE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MALE; MAST CELL; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1; NODULAR PLEXIFORM NEUROFIBROMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HISTAMINE; HISTAMINE RELEASE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MALE; MAST CELLS; MIDDLE AGED; NEUROFIBROMATOSIS 1; SKIN; YOUNG ADULT;

EID: 78649714042     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0938     Document Type: Letter

References (15)

1. Conference Report. Neurofibromatosis: Conference Statement. Arch Neurol 1988; 45: 575-578.
2. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002; 296: 920-922.
3. Yang FC, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for NF1+/- mast cells. J Clin Invest 2003; 112: 1851-1861.
4. Mashour GA, Driever PH, Hartmann M, Drissel SN, Zhang T, Scharf B, et al. Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin Cancer Res 2004; 10: 5677-5683.
5. Le LQ, Parada LF. Tumor microenvironment and neurofibromatosis type 1: connecting the GAPs. Oncogene 2007; 26: 4609-4616.
6. Riccardi VM. Mast-cell stabilization to decrease neurofibroma growth: preliminary experience with ketotifen. Arch Dermatol 1987; 123: 1011-1016.
7. Kamide R, Nomura N, Niimura M. Characterization of mast cells residing in cutaneous neurofibromas. Dermatologica 1989; 179: 124.
8. Khosrotehrani K, Bastuji-Garin S, Riccardi VM, Birch P, Friedman JM, Wolkenstein P. Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients. Am J Med Genet 2005; 132A: 49-53.
9. Weber A, Knop J, Maurer M. Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br J Dermatol 2003; 148: 224-228.
10. Giorno R, Claman HM. Mast cells and neurofibromatosis. Neurofibromatosis 1988; 1: 100-104.
11. Geller M, Ribeiro MG, Araujo AP, de Oliveira LJ, Nunes FP. Serum IgE levels in neurofibromarosis 1. Int J Immunogenet 2006; 33: 111-115.
12. Fabricant RN, Todaro GJ. Increased serum levels of nerve growth factor in von Recklinghausen's disease. Arch Neurol 1981; 38: 401-405.
13. Petersen LJ, Hansen U, Kristensen JK, Nielsen H, Skov PS, Nielsen HJ. Studies on mast cells and histamine release in psoriasis: the effect of ranitidine. Acta Derm Venereol 1998; 78: 190-193.
14. Ring J. Plasma histamine concentrations in atopic eczema. Clin Allergy 1983; 13: 545-552.
15. Amon U, Menz U, Wolff HH. Investigation on plasma levels of mast cell mediators in acute atopic dermatitis. J Dermatol Sci 1994; 7: 63-67.